More informed decisions
Earlier action
Peace of mind
A simple blood draw
Colorectal
Know now with a simple blood draw.*
From a company with more than a decade of experience in oncology blood testing, Guardant Reveal® provides earlier, clearer answers about cancer to help you move forward with confidence.†
What is MRD testing?
Minimal residual disease (MRD) refers to a small amount of cancer that may still be in your body after treatment. These cells can release tiny pieces of DNA into the blood, called circulating tumor DNA (ctDNA).
Guardant Reveal is a blood test that looks for ctDNA and may help detect signs that cancer has returned (also called recurrence), often months before it shows up on a scan or symptoms appear.
Knowing this information helps you and your care team stay a step ahead.
More informed decisions
Earlier action
Peace of mind
Reasons to choose Guardant Reveal
Backed by rigorous scientific studies1-3
Results in about a week*
$0 cost for qualifying Medicare patients‡
Who it’s for: Anyone diagnosed with colorectal, breast, or lung cancer who has finished treatment and has no evidence of disease.
Community stories
Hear what other patients and advocates have to say about Guardant Reveal
Colorectal
If you don't have this kind of testing, you don't have the option to act early. Knowing what's happening gives you a chance to do something about it.
Breast
Our partnerships
Here is a snapshot of our advocacy partners we are proud to work with
Ready to get started?
Ask your doctor if Guardant Reveal is right for you.
Guardant Reveal is available by prescription only.
Helpful resources and services
How Guardant Reveal works
Learn More
Flexible blood draw options at no additional cost§
Mobile Phlebotomy
Coverage and financial assistance
Guardant AccessAbout Guardant Health
Guardant Reveal was developed by Guardant Health, a leading precision oncology company dedicated to helping patients live longer, healthier lives through the power of advanced blood and tissue tests for more than a decade.
1M+
patient samples tested4
15K+
doctors order our tests4
300M+
patients covered through Medicare and major insurance plans‡4
Important Note: Guardant Reveal was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA. Guardant Reveal is not a diagnostic test but used to help guide treatment decisions. A prescription from your healthcare provider is required.
*Median turnaround time from sample receipt to results released to the ordering provider is about a week.
†Refers to detection relative to standard-of-care imaging or clinical presentation.
‡Guardant Reveal is covered by Medicare for all colorectal cancer patients being treated with curative intent both for adjuvant therapy decision-making after surgery and for longitudinal surveillance every 3 to 6 months.
§No additional cost to the patient for Guardant Health phlebotomy services. Patients may incur costs through other phlebotomy services.
References: 1. Nakamura Y, et al. Clin Can Res. 2024. 2. Ademuyiwa FO, et al. Clin Cancer Res. 2025. 3. Elliott MJ, et al. ESMO Open. 2025. 4. Guardant Health data on file. April 2026.
ONC-US-00567